Meet Pharmidex at KTN 2016
June 14, 2016

Collaboration opportunities in regenerative medicine

Pharmdiex will be attending the Innvoate UK KTN 2016 meeting focused on New Collaboration Opportunities in Regenerative Medicine.

The KTN in collaboration with Innovate UK, Cell and Gene Therapy Catapult, Department of Health and Kings College London are holding an event focussing on new unmet clinical needs, latest developments in regulatory environment and clinical adoption. Following recent developments and the UK’s Regenerative Medicine Expert Group report recommendations, this event will bring together the UK regenerative medicine communities involving industrialists, academics and clinicians from a number of clinical specialities.


The UK is leading the field in the development of cell and gene therapies. The regulatory system now has a number of mechanisms to accelerate the progress of promising therapies including EAMS and the proposed new PRIME scheme. However, practical challenges still exist to the clinical adoption of these new therapies and getting them to patients, including generating sufficient clinical data, achieving reimbursement and embedding therapies in existing or new clinical pathways).


Leading clinicians and experts from a number of organisations will be presenting at this event. Directors and managers from major funding organisations, e.g. Innovate UK, Research Councils, relevant charities will also be invited to support this event.


The main aims of this event are as follows;


  • To discuss challenges affecting clinical adoption of cell and gene-based therapies.
  • Facilitate new clinician/industry collaborations in a number of areas of clinical specialities.
  • Identify barriers to innovation and commercialisation.
  • Review current funding opportunities and identify funding gaps.
  • Provide networking opportunities to identify collaborating partners.
  • Review supporting mechanisms available to accelerate innovation and commercialisation through KTN and partners Innovate UK, Cell and Gene Therapy Catapult organisations.
  • Review current pre-clinical and clinical trials and identify best practice to accelerate regulatory approvals


For more information please see the following link: https://www.eventbrite.co.uk/e/new-collaboration-opportunities-in-regenerative-medicine-tickets-24454460951

May 14, 2026
Pharmidex is pleased to announce that Ian Knowles , Head of Respiratory, will be attending ATS 2026 – American Thoracic Society International Conference in Orlando, Florida, from 15–20 May 2026. Ian looks forward to meeting researchers and industry partners to discuss drug discovery and development in asthma, COPD, lung cancer, sepsis, acute respiratory distress, and sleep apnea. Feel free to catch him for a chat!
May 12, 2026
Pharmidex is pleased to announce that Ash Alavijeh , will be attending Bio Integrates 2026 on 14 May 2026 at Victoria House, Bloomsbury, London. Ash looks forward to meeting founders, investors, biotech leaders and scientific partners to discuss drug discovery, translational development and new opportunities across the life sciences sector. He will be delighted to connect with attendees and explore new collaborations and partnerships in the drug development field, feel free to catch him for a chat!
May 11, 2026
We are delighted to welcome Yvonne Squire to the Pharmidex team as our new Senior Histologist. Yvonne brings over 15 years of experience in non-clinical histology and toxicology, with expertise in necropsy, tissue preparation, histochemical techniques and GLP-compliant laboratory operations. Her experience will further strengthen Pharmidex’s histology and translational research capabilities. Welcome to Pharmidex, Yvonne!
More Posts